Author:
Wang Shaojia,Liu Chao,Lei Qing,Wu Zhengwei,Miao Xiangshuai,Zhu Debing,Yang Xu,Li Na,Tang Mingwei,Chen Yan,Wang Weiwei
Abstract
Abstract
Background
Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been used as first-line treatment for advanced non-small-cell lung cancer (NSCLC). However, during treatment, cancer cells often develop resistance to gefitinib, the mechanisms of which are not fully understood. This study was designed to elucidate the expression and role of long non-coding RNA (lncRNA)-PCAT-1, a potential biomarker for drug resistance and a therapeutic target for NSCLC, in gefitinib resistance in NSCLC cells.
Methods
In this study, we verified differential PCAT-1 expression in NSCLC gefitinib-resistant tissues or cells. PCAT-1 knockdown, clone formation, Transwell, flow cytometry, and immunofluorescence assays were used to verify the correlation between PCAT-1 and gefitinib sensitivity. A nude mouse tumor-bearing model verified that PCAT-1 can reverse gefitinib resistance in vivo. Then, a PI3K/Akt agonist was used to verify the possible mechanism of PCAT-1 action.
Results
PCAT-1 is highly expressed in gefitinib-resistant NSCLC tissues and cells. PCAT-1 knockdown enhanced gefitinib sensitivity and gefitinib-induced apoptosis in H1299/GR cells. PCAT-1 knockdown reduced tumor volume and weight, and reversed acquired gefitinib resistance in vivo. PCAT-1 knockdown inhibited AKT and GSK3 phosphorylation in H1299/GR cells. A PI3K/AKT agonist reversed PCAT-1 knockdown-mediated enhancement of gefitinib sensitivity in H1299/GR cells
Conclusion
PCAT-1 knockdown improves sensitivity to gefitinib by inhibition of AKT and GSK3 phosphorylation in NSCLC. PCAT-1 is as potential target for improving the clinical efficacy of gefitinib.
Funder
Regional Program of National Natural Science Foundation of China
Youth Program of National Natural Science Foundation of China
Basic research in Yunnan Province
Natural Science Foundation, Regional Science Foundation Project
National Natural Science Foundation of China
Project of Medical and Health Technology Development Program of Yunnan Province
Academic Leaders Training Program of Yunnan Provincial Health and Family Planning Commission
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Siegel R, Miller K, Jemal A. Cancer statistics. CA Cancer J Clin. 2017;67(1):7–30 (PMID; 2017).
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA. 2016;66:115–32.
3. Shroff GS, Benveniste MF, De Groot PM, Wu CC, Viswanathan C, Papadimitrakopoulou VA, Truong MT. Targeted therapy and imaging findings. J Thorac Imaging. 2017;32:313–22.
4. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. In Mayo clinic proceedings. Elsevier; 2008: 584–594.
5. Zhang H. Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther. 2015;9:6075–81.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献